Topic

Weight loss peptides and medications

Losing weight is less about willpower than about biology: hunger hormones, blood sugar swings, and metabolism all push back. These articles look at the weight loss peptides and medications researchers study — how they work, what results have been measured, and what a realistic plan looks like alongside food and movement.

Nothing here is a shortcut or a guarantee. Medication is one tool, prescribed only when a licensed provider decides it fits your situation. Every article below is specific about what was measured and in whom.

135 articles on this topic

  1. A man sits on a small balcony peeling an orange

    Tirzepatide Telehealth Study: 15.5% Loss at Six Months

    A large UK digital program tracked 8,127 women starting treatment, almost all on tirzepatide. Women with six-month weigh-ins lost an average of 15.5% of their starting weight, though study limits matter.

    October 17, 2026 · Julian Reyes, Health Writer
  2. A woman sits on the edge of a raised garden bed holding gardening gloves

    STEP 5 Trial Results: Semaglutide at Two Years

    In STEP 5, average weight loss was 15.2% with semaglutide versus 2.6% with placebo at two years. The plateau, side effects and two calculations explain what held up.

    October 12, 2026 · Priya Raman, Health Writer
  3. Two friends sit together on a driftwood log above a quiet beach with a glass of water

    Semaglutide Knee Osteoarthritis: What STEP 9 Found

    In STEP 9, adults with obesity had greater average knee-pain and weight reductions with semaglutide. The trial did not establish cartilage repair.

    October 11, 2026 · Elena Marsh, Health Writer
  4. A man sits on a mat in a bright studio with a glass of water

    Zenagamtide: Amycretin’s New Name, Still in Trials

    Zenagamtide is amycretin’s new name: an experimental drug being tested as a weekly shot and a daily pill. Here’s what the trials actually found.

    October 11, 2026 · Nadia Okonjo, Health Writer
  5. A ball of undyed wool yarn on plain linen, a close view

    Tirzepatide and Thyroid: Levothyroxine Checks

    An underactive thyroid doesn't automatically rule out tirzepatide. Weight loss and changes in tablet absorption can make a thyroid-dose review worthwhile.

    October 10, 2026 · Priya Raman, Health Writer
  6. Two friends sit together on a window seat holding a pot of seedlings

    OASIS 4 Trial Results: 13.6% Weight Loss Explained

    The daily 25 mg tablet averaged 13.6% weight loss versus 2.2% with placebo at 64 weeks. The 16.6% headline assumes continued treatment.

    October 9, 2026 · Priya Raman, Health Writer
  7. Two friends sit together on a bench in a utility room with a plain mug

    STEP UP Trial Results: 7.2 mg Versus 2.4 mg

    STEP UP compared two semaglutide doses with placebo over 72 weeks. The higher dose brought more weight loss and more stomach and skin symptoms.

    October 7, 2026 · Julian Reyes, Health Writer
  8. A man sits on the bottom step of a staircase with a ball of yarn

    Semaglutide and Gallbladder: Risks and Symptoms

    Gallstones were more common in semaglutide trials, but most participants did not report them. Here are the Wegovy and Ozempic rates and the symptoms that need urgent care.

    October 6, 2026 · Priya Raman, Health Writer
  9. A woman sits on a stool beside a kitchen window with a wooden bowl

    Semaglutide and Menopause: Weight, HRT and Bone

    Semaglutide may help with medically appropriate weight management after menopause. Hormone therapy, muscle, bone, and menopause symptoms each need their own place in the care plan.

    October 6, 2026 · Elena Marsh, Health Writer
  10. Three lemons on plain linen, a close view

    STEP-HFpEF Results: Symptoms, Weight and Limits

    Semaglutide improved symptoms and walking distance in two year-long trials of adults with obesity and heart failure. Here are the results, side effects and limits.

    October 6, 2026 · Priya Raman, Health Writer
  11. A woman stands beside a bicycle in a quiet lane holding an apple

    Open Enrollment GLP-1 Coverage: 2027 Checklist

    Coverage depends on the exact plan, product, and reason for prescribing. This fall's checklist covers dates, approval rules, refill costs, and Medicare's separate Bridge program.

    October 6, 2026 · Nadia Okonjo, Health Writer
  12. An empty bench in a quiet gym

    Semaglutide for PCOS: Weight Loss and Periods

    Semaglutide may help with weight loss in some people with PCOS. Evidence for more regular periods is growing, while pregnancy plans change the decision.

    October 5, 2026 · Elena Marsh, Health Writer
  13. A woman sits on a sofa in a quiet living room holding a pear

    Semaglutide for Sleep Apnea: What Studies Show

    Semaglutide may help with weight management when obesity contributes to sleep apnea. It isn't approved to treat sleep apnea and doesn't replace prescribed CPAP.

    October 5, 2026 · Nadia Okonjo, Health Writer
  14. A man sits on a window seat with a folded scarf

    SURMOUNT-3 Results: More Weight Loss After Diet

    After an average 6.9% loss through diet and exercise, selected trial participants lost another 18.4% on tirzepatide. Participants receiving an injection without tirzepatide gained 2.5% over the same 72 weeks.

    October 5, 2026 · Priya Raman, Health Writer
  15. A man sits on a small balcony holding a pot of seedlings

    Phases of Clinical Trials: What 1, 2, 3 and 4 Mean

    Phase 1 checks early safety. Phases 2 and 3 test treatment effects, and phase 4 studies medicines after they reach the market.

    October 5, 2026 · Julian Reyes, Health Writer
  16. A woman sits at a plain kitchen table peeling an orange

    Should I Take MOTS-c? Start With These Questions

    MOTS-c isn't an established treatment for weight loss or tiredness. A provider weighs the thin human evidence, your medicines and sports rules before deciding whether it fits.

    October 4, 2026 · Julian Reyes, Health Writer
  17. A woman sits on a mat in a bright studio with a glass of water

    STEP 4 Trial Results: Continuing vs Stopping

    After 20 weeks on semaglutide, people who continued lost more weight. Those switched to placebo regained weight despite continued lifestyle support; who reached that switch shapes the answer.

    October 3, 2026 · Julian Reyes, Health Writer
  18. A woman sits on a stool beside a kitchen window holding a lemon

    When Did the Tirzepatide Shortage End? The Dates

    The FDA took tirzepatide off its shortage list on October 2, 2024. A lawsuit, a second decision and two grace periods followed. Here is the timeline, read from the FDA's own documents, and what it means for a prescription today.

    October 2, 2026 · Julian Reyes, Health Writer
  19. A woman sits on a park bench under trees holding a tennis ball

    Semaglutide and Blood Pressure: How Much It Drops

    In the main weight-loss trial, the top number fell about 5 points more on semaglutide than on placebo, mostly riding on weight loss. Here is what that gap looks like, who sees more of it, and when a falling reading needs a second look.

    October 1, 2026 · Priya Raman, Health Writer
  20. Two friends sit together on a sofa in a quiet living room

    SURMOUNT-4 Results: What Stopping Tirzepatide Did

    SURMOUNT-4 gave adults tirzepatide for 36 weeks, then switched half of them, by chance, to a look-alike placebo. Over the next year the placebo group regained much of its loss while the other half kept losing, and who made it to that switch shapes what the trial can tell you.

    October 1, 2026 · Nadia Okonjo, Health Writer

Page 1 of 7 · 135 articles